source
- Amylyx to seek FDA approval for avexitide after Phase 3 success in post-bariatric hypoglycemiaAmylyx announced plans to file a new drug application for avexitide, a GLP-1 receptor antagonist, after a Phase 3 trial showed reduction in serious hypoglycemia in patients who had gastric bypass s…
- Leo Pharma to license Tanabe’s oral drug for rare light-sensitive skin disease, paying up to $435 millionLeo Pharma announced a licensing agreement with Japan's Tanabe Pharma for an oral treatment targeting two genetic skin disorders that cause pain when exposed to sunlight. Under the deal, Leo Pharm…